Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add filters








Language
Year range
1.
Chinese Journal of Natural Medicines (English Ed.) ; (6): 290-293, 2014.
Article in English | WPRIM | ID: wpr-812263

ABSTRACT

The incidence of diabetes has increased considerably, and become the third serious chronic disease following cancer and cardiovascular diseases. Though acarbose, metformin, and 1-deoxynojirimycin have good efficacy for clinical application as hypoglycemic drugs, their expensive costs and some degree of side effects have limited their clinical application. Recently, increasing attention has concentrated on the polysaccharides from natural plant and animal sources for diabetes. In order to illustrate the pharmaceutical activity of polysaccharides as natural hypoglycemic agents, polysaccharides isolated from Astragalus, oyster mushroom, and Yacon were evaluated for their inhibitory effects on α-glucosidase. Polysaccharides were extracted and purified from Astragalus, Oyster mushroom, and Yacon with hot water at 90 °C for 3 h, respectively. The total sugar content of the polysaccharide was determined by the phenol-sulfuric acid method. The α-glucosidase inhibitory activity was measured by the glucose oxidase method. The results exhibited that the inhibitory effects on α-glucosidase were in decreasing order, Astragalus > oyster mushroom > Yacon. The α-glucosidase inhibition percentage of Astragalus polysaccharide and oyster mushroom polysaccharide were over 40% at the polysaccharide concentration of 0.4 mg·mL(-1). The IC50 of Astragalus polysaccharide and oyster mushroom polysaccharide were 0.28 and 0.424 mg·mL(-1), respectively. The information obtained from this work is beneficial for the use polysaccharides as a dietary supplement for health foods and therapeutics for diabetes.


Subject(s)
Humans , Asteraceae , Chemistry , Astragalus Plant , Chemistry , Diabetes Mellitus , Drugs, Chinese Herbal , Chemistry , Pharmacology , Glycoside Hydrolase Inhibitors , Chemistry , Pharmacology , Pleurotus , Chemistry , Polysaccharides , Chemistry , Pharmacology , alpha-Glucosidases , Chemistry
2.
Biomedical and Environmental Sciences ; (12): 17-26, 2014.
Article in English | WPRIM | ID: wpr-247091

ABSTRACT

<p><b>OBJECTIVE</b>To study the effect of spleen lymphocytes on the splenomegaly by hepatocellular carcinoma-bearing mouse model.</p><p><b>METHODS</b>Cell counts, cell cycle distribution, the percentage of lymphocytes subsets and the levels of IL-2 were measured, and two-dimensional gel electrophoresis (2-DE) was used to investigate the relationship between spleen lymphocytes and splenomegaly in hepatocellular carcinoma-bearing mice.</p><p><b>RESULTS</b>Compared with the normal group, the thymus was obviously atrophied and the spleen was significantly enlarged in the tumor-bearing group. Correlation study showed that the number of whole spleen cells was positively correlated with the splenic index. The cell diameter and cell-cycle phase distribution of splenocytes in the tumor-bearing group showed no significant difference compared to the normal group. The percentage of CD3+ T lymphocytes and CD8+ T lymphocytes in spleen and peripheral blood of tumor-bearing mice were substantially higher than that in the normal mice. Meanwhile, the IL-2 level was also higher in the tumor-bearing group than in the normal group. Furthermore, two dysregulated protein, β-actin and S100-A9 were identified in spleen lymphocytes from H22-bearing mice, which were closely related to cellular motility.</p><p><b>CONCLUSION</b>It is suggested that dysregulated β-actin and S100-A9 can result in recirculating T lymphocytes trapped in the spleen, which may explain the underlying cause of splenomegaly in H22-bearing mice.</p>


Subject(s)
Animals , Female , Mice , Carcinoma, Hepatocellular , Cell Cycle , Liver Neoplasms , Lymphocytes , Physiology , Mice, Inbred ICR , Neoplasms, Experimental , Therapeutics , Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization , Spleen , Cell Biology , Pathology , Splenomegaly , Therapeutics , Thymus Gland
SELECTION OF CITATIONS
SEARCH DETAIL